Sun Pharma introduces Ilumya in India for treatment of plaque psoriasis
Ilumya is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials
Ilumya is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials
Soficitinib is a potent and selective TYK2 inhibitor under development for multiple T-cell mediated autoimmune disorders
The Complement Laboratory is equipped with state-of-the-art immunoturbidimetric and ELISA platforms and adheres to CAP and NABL accreditation standards
The State’s PPP model has already mobilised Rs. 150 crore in core infrastructure, while Thermo Fisher has invested Rs. 90 crore in the Bioprocess Design Centre and its co-located Customer Experience Centre
According to the ICMR-INDIAB study, 11.4% of adults in India have type 2 diabetes, while a staggering 15.3% are pre-diabetic
India presents one of the world’s largest untapped opportunities for neurovascular screening
Both companies will promote, market and distribute Sodium Zirconium Cyclosilicate in India under different brand names
The FDA is initiating removal of the boxed warnings following a comprehensive review of the scientific literature
Subscribe To Our Newsletter & Stay Updated